PROGNOSTIC FACTORS FOR CYTOMEGALOVIRUS DISEASE IN KIDNEY TRANSPLANT RECIPIENTS WITH CYTOMEGALOVIRUS VIREMIA AT MILITARY HOSPITAL 103 DURING THE PERIOD 2022–2025

Minh Nam Nguyễn1, , Văn Nam Lê1, Việt Phương Nguyễn1, Quang Thuận Bùi1
1 Bộ môn khoa Truyền nhiễm, Bệnh viện Quân y 103

Main Article Content

Abstract

Objective: To identify some prognostic factors for Cytomegalovirus (CMV) disease in kidney transplant recipients with CMV viremia at Military Hospital 103 during the period 2022–2025.


Subjects and Methods: A descriptive study combining retrospective and prospective approaches was conducted on 87 kidney transplant recipients with CMV viremia diagnosed by Real-time PCR at Military Hospital 103 (2022–2025). Patients were divided into two groups: asymptomatic CMV infection and CMV disease.


Results: CMV disease accounted for 71.26% of kidney transplant recipients with CMV viremia. The timing of CMV occurrence after transplantation was associated with clinical manifestations, with late-onset CMV infection (> 6 months after transplantation) being more common in the CMV disease group (46.77% vs. 20.00%; p < 0.001). The CMV disease group had a higher rate of thrombocytopenia compared with the asymptomatic CMV infection group (38.71% vs. 0%; p = 0.004). Elevated CRP levels and decreased albumin concentrations were associated with CMV disease (p = 0.043 and 0.035, respectively).


Conclusion: In kidney transplant recipients with CMV viremia, late-onset CMV infection after transplantation, increased CRP levels, decreased platelet count and decreased albumin were associated with CMV disease.

Article Details

References

1. G. K. Jesus, R. Costa, G. O. Franco. et al (2026) Incidence of Cytomegalovirus (CMV) Infection in After Kidney Transplant Patients: A Systematic Review and Meta-Analysis. Rev Med Virol.36 (1): e70092.
2. S. K. Arthurs, A. J. Eid, R. A. Pedersen. et al (2008) Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis.46 (6): 840-846.
3. Y. Tang, J. Guo, J. Li. et al (2022) Risk factors for cytomegalovirus infection and disease after kidney transplantation: A meta-analysis. Transpl Immunol.74: 101677.
4. I. Helanterä, L. Kyllönen, I. Lautenschlager. et al (2010) Primary CMV infections are common in kidney transplant recipients after 6 months valganciclovir prophylaxis. Am J Transplant.10 (9): 2026-2032.
5. G. Ono, J. O. Medina Pestana and L. F. Aranha Camargo (2019) Late cytomegalovirus (CMV) infections after kidney transplantation under the preemptive strategy: Risk factors and clinical aspects. Transpl Infect Dis.21 (2): e13035.
6. C. Léonard, B. Taton, E. Lazaro. et al (2025) Thrombocytopenia following kidney transplantation: a frequent, underestimated and potentially severe complication. Front Immunol.16: 1519256.
7. E. C. Costalonga, N. C. Melo, C. E. Rodrigues. et al (2009) The potential role of C-reactive protein in distinguishing cytomegalovirus from tuberculosis and bacterial infections in renal transplant recipients. Clin Transplant.23 (5): 710-715.
8. Carlo Maria Alfieri, Paolo Molinari, Mariateresa Gandolfo. et al (2021) Cytomegalovirus Disease in Renal Transplanted Patients: Prevalence, Determining Factors, and Influence on Graft and Patients Outcomes. Pathogens.10 (4): 473.